Derek J Maetzold, President and Chief Executive Officer of Castle Biosciences Inc (NASDAQ:CSTL), sold 9,748 shares of the company's common stock on April 6, 2026, at an effective price of $25.03 per share, for a total value of $246,195.
The transactions were executed across multiple trades at prices that ranged from $24.64 to $25.29. On the same day, Maetzold exercised stock options to acquire 6,214 shares of Castle Biosciences common stock at an exercise price of $2.39 per share, representing a total cost of $14,851.
As of the latest quote, Castle Biosciences stock is trading at $25.21. The share price is down 36% year-to-date but remains 73% above its 52-week low of $14.59.
Financial and research context provided by third-party analysis indicates the company holds more cash than debt on its balance sheet and carries a Financial Health Score labeled as "GREAT" at 3.04, according to InvestingPro. The platform's Fair Value analysis suggests that the stock may be undervalued and notes that six additional ProTips are available to subscribers. Investors seeking more detailed analysis can consult the platform's Pro Research Report on CSTL.
Recent company disclosures also include fourth-quarter 2025 financial results that beat consensus expectations on both the top and bottom lines. Castle Biosciences reported a diluted loss per share of $0.08 for the quarter, which was narrower than the consensus forecasted loss of $0.32 - a variance characterized as a 75% positive surprise. Quarterly revenue was reported at $87 million, exceeding the anticipated $77.09 million by 12.86%.
Canaccord Genuity reiterated a Buy rating on Castle Biosciences following the results and maintained a $50 price target. Management attributed the revenue increase to higher year-over-year volumes for the majority of the company’s diagnostic tests.
On the clinical front, Castle Biosciences presented data at the American Academy of Dermatology Annual Meeting showing that its DecisionDx-Melanoma test stratifies mortality risk within specific cancer stages. That analysis used registry data from 1,868 patients with stage I-III cutaneous melanoma who were tested between 2013 and 2019.
The disclosed insider sale, concurrent option exercise, stronger-than-expected quarterly performance, and presentation of clinical data together paint a composite snapshot of recent corporate activity. The company’s balance-sheet position and external analyses are noted in available third-party research sources referenced above.